Acumen Pharmaceuticals, Inc. Proceeds from Debt, Net of Issuance Costs
Acumen Pharmaceuticals, Inc. (ABOS) reported Proceeds from Debt, Net of Issuance Costs of $29.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-03-27
- Acumen Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $29.50M, a 0.00% change from fiscal 2023.
- Acumen Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $29.50M.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|
| 2024-12-31 | $29.50M 10-K · filed 2025-03-27 |
| 2023-12-31 | $29.50M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |